A new study published in The Lancet, analyzing over 58,000 participants, revealed significant variations in physiological side effects across 30 different antidepressants, including changes in weight, heart rate, blood pressure, and cholesterol. For example, some medications like maprotiline were linked to weight gain, while others such as agomelatine were associated with weight loss. The research emphasizes the need for more personalized antidepressant treatment plans to better match patient health and preferences, rather than deterring the use of these effective medications, as untreated depression also carries health risks.
A recent Lancet study, encompassing over 58,000 participants, revealed significant physiological side effect variations across 30 different antidepressants. The research identified "clinically significant" differences in drug impact on weight, heart rate, blood pressure, and cholesterol compared to placebo over an eight-week average. Specific findings include maprotiline's association with an average 4-pound weight gain in nearly half of users, contrasting with agomelatine's average 5.5-pound weight loss in 55% of patients. Heart rate effects also varied, with nortriptyline increasing it by 14 bpm and fluvoxamine decreasing it by 8 bpm, though kidney and liver functions were largely unaffected. This study underscores the critical need for personalized antidepressant treatment, advocating for better tailoring to individual patient health and preferences rather than deterring medication use. The findings suggest a potential industry shift towards more sophisticated diagnostic and prescriptive approaches within mental health, emphasizing drug-specific side effect profiles.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
neutral
Sentiment Score
0.00
